CHICAGO, Aug. 16, 2012 /PRNewswire/ -- Positron
Corporation (OTCBB: POSC) a leading molecular imaging healthcare
company is pleased to announce the use of their Attrius system at
Caring Heart and Brain Imaging Inc., of Manasquan, New Jersey, which now offers Amyvid
PET scans to identify the presence of plaque in the
brain, which has been shown to be a precursor to Alzheimer's
disease.
Amyvid™ (Florbetapir F-18 Injection) is indicated for Positron
Emission Tomography (PET) imaging of the brain to estimate
beta-amyloid neuritic plaque density in adult patients with
cognitive impairment who are being evaluated for Alzheimer's
Disease (AD) and other causes of cognitive decline.
Alzheimer's disease is the most common cause of dementia—a group
of brain disorders that cause progressive loss of intellectual and
social skills, severe enough to interfere with day-to-day life. In
Alzheimer's disease, brain cells degenerate and die, causing a
steady decline in memory and mental function.
"Current AD medications and management strategies can
temporarily improve symptoms, maximize function and maintain
independence and we are pleased that our Attrius PET system could
possibly help with the identification and management of this
disease," stated Joseph Oliverio,
Chief Technology Officer and Director of PET Clinical Programs of
Positron.
Lorraine Catalano, Imaging
Director of Caring Heart stated, "Alzheimer's disease can now be
diagnosed several years before the onset of symptoms. Early
detection can lead to innovative programs designed to treat memory
loss. This alternative can make the difference between a life of
constant hardship or one that is fulfilled and remains on top of
its game."
Anthony Deluca, M.D., Medical
Director of Caring Heart and Brain Imaging stated, "We are pleased
to be the first in New Jersey to
offer this service. We are also delighted with the image
quality that the Attrius scanner provides."
About Positron:
Positron Corporation is a leading molecular imaging healthcare
company vertically integrating all the segments of nuclear
cardiology—providing an end-to-end solution for cardiac PET.
Through proprietary PET imaging systems, radiopharmaceuticals and
radioisotopes solutions, Positron enables healthcare providers to
more accurately diagnose disease and improve patient outcomes,
while practicing cost effective medicine. Positron's unique
products, market position and approach in securing the supply chain
are substantial advantages, further accelerating the adoption of
cardiac PET and growth of nuclear cardiology. Positron is
redefining the industry. More information about Positron is
available at www.positron.com.
About Caring Heart and Brain Imaging:
Caring Heart and Brain Imaging Inc. is the first dedicated
cardiac and brain PET imaging facility in the State of New Jersey, located at 2414 Highway
35N in Manasquan, NJ. Along
with an expert staff dedicated to patient comfort and peace of
mind, we bring over 30 years of experience: Anthony Deluca, MD and Lorraine Catalano, CNMT, have been active in the
medical field as family practice specialist and nuclear medicine
technologist, respectively. Dr. Deluca has developed a close
referring relationship to his cardiology and neurology colleagues
and Lorraine Catalano has a shared
perspective as a technologist performing Nuclear Cardiology and
Nuclear Brain scans for more than 15 years. Debra Schneider directs all facility procedures
with expertise and compassion and our patient coordinator,
Lil Hogan, always greets patients
with respect and consideration. Together this team ensures
that Caring Heart and Brain's commitment to patient care is
maintained and fulfilled. Patients will be imaged in a warm
and comfortable environment, like no other. We will take care
of you like family and scan you with caring hands. www.chci.biz
Forward Looking Statements: Statements in this
document contain certain forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933 and Section
21E of the Securities Exchange Act of 1934, as amended. These
statements are based on many assumptions and estimates and are not
guarantees of future performance. These statements may involve
known and unknown risks, uncertainties and other factors which may
cause the actual results, performance or achievements of Positron
Corporation to be materially different from future results,
performance or achievements expressed or implied by such
forward-looking statements. Positron assumes no obligation to
publicly update or revise these forward-looking statements for any
reason, or to update the reasons actual results could differ
materially from those anticipated in these forward-looking
statements, even if new information becomes available in the
future. Our actual results may differ materially from the
results anticipated in these forward-looking statements due to a
variety of factors, including, without limitation those set forth
as "Risk Factors" in our filings with the Securities and Exchange
Commission.
SOURCE Positron Corporation